AbbVie Header AbbVie Header

X

Find the latest Drugs in Development and Pipeline Prospector News of Zydus Lifesciences.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Zydus Lifesciences
india-flag Flag
Country
Country
India
Address
Address
Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej - Gandhinagar Hwy, Ahmedabad, 382481
Telephone
Telephone
91 2262801310

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Through the acquisition, Sentynl will commercialize the Zokinvy (lonafarnib) globally. It is the first and only treatment approved by the U.S. FDA to target the cause and symptoms of progeria, also known as Hutchinson-Gilford progeria syndrome.


Lead Product(s): Lonafarnib

Therapeutic Area: Genetic Disease Product Name: Zokinvy

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Eiger BioPharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition May 03, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Myrbetriq- Generic (mirabegron) is a beta-3 adrenergic receptor inhibitor which has been approved by FDA for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.


Lead Product(s): Mirabegron

Therapeutic Area: Urology Product Name: Myrbetriq-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

NULIBRY (fosdenopterin) for Injection, the first therapy for the treatment of patients in Great Britain with molybdenum cofactor deficiency Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants.


Lead Product(s): Fosdenopterin

Therapeutic Area: Rare Diseases and Disorders Product Name: Nulibry

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Ibyra (olaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor, which is approved in India for the treatment of HRD-positive and BRACA-positive cancer patients.


Lead Product(s): Olaparib

Therapeutic Area: Oncology Product Name: Ibyra

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 13, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Saroglitazar is a first in class drug which acts as a dual PPAR agonist at the subtypes α (alpha) and γ (gamma). It is being evaluated for the treatment of Primary Biliary Cholangitis.


Lead Product(s): Saroglitazar magnesium

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Imdur-Generic (isosorbide mononitrate) is a soluble guanylate cyclase activator which is approved by USFDA for the treatment of chest pain (angina) in patients with a certain heart condition.


Lead Product(s): Isosorbide Mononitrate

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Imdur-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 16, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Rexigo (relugolix) is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors. It is launched in India for testosterone suppression in patients with advanced prostate cancer.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Product Name: Rexigo

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 01, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Prezista (darunavir) is a protease inhibitor antiviral medicine which is approved by USFDA for the treatment of Human Immunodeficiency Virus (HIV-1) Infection.


Lead Product(s): Darunavir

Therapeutic Area: Infections and Infectious Diseases Product Name: Prezista

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 15, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, Zydus will assume full responsibility for the clinical development and commercialization for leuprolide injectable in the US market, and Daewoong will be responsible for the pre-clinical studies, production and supply of the product.


Lead Product(s): Leuprolide Acetate

Therapeutic Area: Oncology Product Name: Lupron Depot-Generic

Highest Development Status: ApprovedProduct Type: Peptide

Recipient: Daewoong Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement December 12, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to comarket an innovative drug, Rytstat (desidustat), first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease, in India.


Lead Product(s): Desidustat

Therapeutic Area: Hematology Product Name: Rytstat

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement October 30, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY